STOCKHOLM – February 22, 2023 – Inify Laboratories, a company providing fully digitalized laboratory services within prostate cancer diagnostics, has completed its new laboratory – including staffing up with skilled professionals – in less than a year.
“The laboratory has been finished in record time. We now have an ultramodern AI-based laboratory, and a dedicated team with a broad spectrum of expertise within digital pathology,” says CEO Fredrik Palm at Inify Laboratories.
“Reached all milestones”
Total costs so far are in line with our expectations, due to good project planning and successful teamwork within the company’s interdisciplinary teams, as well as close collaboration with external suppliers.
“The fourth quarter sees us reaching practically all the milestones required to be able to start the new year with tests and validation of our complete system before we launch our diagnostic service for prostate cancer. The launch is expected to take place in the first half of 2023,” says Palm.
“Setting a new world standard”
In early October, the company carried out successful tests of its unique IT system, where every part of the process is standardized with full traceability. The feedback from future customers – urology clinics and pathologists, with whom Inify has had a close dialogue – has been highly positive.
“The response exceeded our already high expectations, and we close the year with strong confidence that our first patients will be diagnosed according to schedule,” says Palm. “We continue at full speed towards our goal – setting a new world standard in pathological cancer diagnostics, for the benefit of doctors and patients.”
For further information, please contact CEO Fredrik Palm, , or visit www.inify.com.
About Inify Laboratories
Inify Laboratories is currently building and establishing an ultramodern laboratory that will provide cancer diagnostics within histopathology. Designed from scratch, it uses a fully digital, standardized and AI-supported workflow to optimize quality and shorten response times, initially within prostate cancer. The first laboratory, located at Campus Solna Sweden, is estimated to start offering services to both public and private healthcare providers before summer 2023.
The company originates from ContextVision, with nearly 40 years of experience within digital imaging for medical applications and became independent through a spin-off in February 2022. The company, based in Sweden, is listed on Euronext Growth Oslo under the ticker INIFY.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.